A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
2021 · Nature Medicine · 199 citations
https://doi.org/10.1038/s41591-021-01544-x
E
Eva Ellebæk
Herlev Hospital(DK)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
150
Papers
2.8K
Citations
24
h-index
37
i10-index
Eva Ellebæk is an academic researcher from Herlev Hospital. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & CAR-T cell therapy research & Immunotherapy and Immune Responses. The author has an h-index of 24, co-authored 128 publications.
ORCID: 0000-0001-6748-9232Papers by this author
worksAdoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients
2012 · Journal of Translational Medicine · 164 citations
https://doi.org/10.1186/1479-5876-10-169
Characterization and Comparison of ‘Standard’ and ‘Young’ Tumour‐Infiltrating Lymphocytes for Adoptive Cell Therapy at a Danish Translational Research Institution
2011 · Scandinavian Journal of Immunology · 105 citations
https://doi.org/10.1111/j.1365-3083.2011.02640.x
Adjuvant treatment for melanoma in clinical practice – Trial versus reality
2021 · European Journal of Cancer · 32 citations
https://doi.org/10.1016/j.ejca.2021.08.044
PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma
2023 · European Journal of Cancer · 30 citations
https://doi.org/10.1016/j.ejca.2023.113476
Quality of life and mental health in real-world patients with resected stage III/IV melanoma receiving adjuvant immunotherapy
2023 · Acta Oncologica · 19 citations
https://doi.org/10.1080/0284186x.2023.2165449
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat